by Robert A. Kyle, and S. Vincent Rajkumar

Slides:

Advertisements

Similar presentations

Multiple Myeloma: ASH 2005 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine.

Advertisements

Atypical Fractures of the Femur: Evaluation and Treatment by Travis Blood, R.J. Feller, Eric Cohen, Christopher T. Born, and Roman Hayda JBJS Reviews Volume.

Thalidomide, Radiation, and Peripheral Stem Cell Transplantation as Combination Treatment for Multiple Myeloma Allison Reczek Department of Biological.

1.Defining Plasma cell disorders/Multiple Myeloma 2.Identification of different plasma cell disorders. 3.Diagnosis and workup for plasma cell disorders/Multiple.

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma by Sonja Zweegman, Bronno van der Holt,

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

Sarah Kunin, MD Princeton Baptist Medical Center Baptist Health Systems Alabama Multiple Myeloma: Treatment with Bisphosphonates.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Attal M et al. Proc ASH 2010;Abstract 310.

Andrzej Jakubowiak Seminars in Hematology

Dr WAQAR ASST. PROFESSOR INTERNAL MEDICINE

Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study by Henk M. Lokhorst, Bronno van der.

Treatment of Immunoglobulin Light Chain Amyloidosis

How I treat extramedullary myeloma

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)‏ by Antonio Palumbo,

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Alternate designs for conduct and analysis of phase I cancer trials

How I treat multiple myeloma in younger patients

Multiple Myeloma: Interleukin-15 Antagonizes Bone Morphogenetic Protein-Induced Apoptosis and Growth Inhibition. by Magne Rekvig, Anne-Tove Brenne, Torstein.

by Timothy P. Hughes, and David M. Ross

How I treat autoimmune hemolytic anemias in adults

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma by Lotta.

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.

BTK inhibition in myeloma: targeting the seed and the soil

by Rafael Fonseca, Richard J. Bailey, Gregory J. Ahmann, S

Enlightening light chain deposition disease

Multiple Myeloma: Diagnosis and Treatment

Transplants for the elderly in myeloma

Current Therapy for Multiple Myeloma

How I treat elderly patients with myeloma

Critiquing Cryos by Morie Gertz Blood Volume 111(11):

A young patient with multiple myeloma

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.

The role of complete response in multiple myeloma

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping by David C. Johnson, Sophie Corthals,

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.

Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma by Massimo.

Solitary plasmacytoma of bone and asymptomatic multiple myeloma

by Sabah Sallah, and Jim Y. Wan

by Karl-Georg Fischer, Barbara Deschler, and Michael Lübbert

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Stage C or not stage C…? by Claire Dearden Blood

Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma by Mohammed A. Aljama, M. Hasib Sidiqi, Arjun.

ROCK and Rho(ll) in bone marrow

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone by Patrizia Tosi, Elena.

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,

Managing Multiple Myeloma in the Elderly

Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors by Teal S. Hallstrand,

Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines.

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

JBMR 2012;doi:[ /jbmr.1760] (Fig. 3A)

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

by Giovanni Palladini, and Giampaolo Merlini

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

by Wendy Lim, Sara K. Vesely, and James N. George

Treatment versus Transplant for Challenging Hematologic Disorders

Treatment algorithm for management of CRS based on the revised CRS grading system. Treatment algorithm for management of CRS based on the revised CRS grading.

The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management by Elias J. Anaissie, Tahsine.

An algorithmic approach to FL

Pure red cell aplasia by Robert T. Means Blood

Suggested algorithm for bone marrow biopsy and skeletal imaging in patients with monoclonal gammopathy of undetermined significance. #Mayo Clinic Risk.

by Lapo Alinari, and Kristie A. Blum

Initial treatment of CLL: integrating biology and functional status

How I treat T-cell acute lymphoblastic leukemia in adults

Presentation transcript:

by Robert A. Kyle, and S. Vincent Rajkumar Multiple myeloma by Robert A. Kyle, and S. Vincent Rajkumar Blood Volume 111(6):2962-2972 March 15, 2008 ©2008 by American Society of Hematology

Robert A. Kyle, and S. Vincent Rajkumar Blood 2008;111:2962-2972 ©2008 by American Society of Hematology

Robert A. Kyle, and S. Vincent Rajkumar Blood 2008;111:2962-2972 ©2008 by American Society of Hematology

Timeline depicting the history and treatment of multiple myeloma from 1844 to the present. Robert A. Kyle, and S. Vincent Rajkumar Blood 2008;111:2962-2972 ©2008 by American Society of Hematology

Sarah Newbury, the first reported patient with multiple myeloma. Sarah Newbury, the first reported patient with multiple myeloma. (A) Bone destruction in the sternum. (B) The patient with fractured femurs and right humerus. (C) Bone destruction involving the femur. Adapted from Solly7 with permission. Robert A. Kyle, and S. Vincent Rajkumar Blood 2008;111:2962-2972 ©2008 by American Society of Hematology

(A) Henry Bence Jones. (A) Henry Bence Jones. (B) Otto Kahler (courtesy of Dr Heinz Ludwig, Vienna). (C) Jan Waldenström (courtesy of Giampaolo Merlini, Pavia, Italy). Robert A. Kyle, and S. Vincent Rajkumar Blood 2008;111:2962-2972 ©2008 by American Society of Hematology

Algorithm outlining the current approach to the treatment of newly diagnosed myeloma. Algorithm outlining the current approach to the treatment of newly diagnosed myeloma. CR indicates complete response; MPT, melphalan, prednisone, thalidomide; and VGPR, very good partial response. Robert A. Kyle, and S. Vincent Rajkumar Blood 2008;111:2962-2972 ©2008 by American Society of Hematology